Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial

Abstract

We read with great interest the article by Grünberger et al. on the ‘blind’ administration of doxycycline in a retrospective series of 11 patients with ocular adnexal lymphoma of MALT-type (OAL) [1]. Authors used this therapy on the basis that, in the Italian experience [2], most cases of OAL were shown to be related to chlamydial infection. However, a centralized molecular assessment of chlamydial infection was not performed, and no clinical responses were observed after a median follow-up of 9 months [1].